Personalis (PSNL)
NASDAQ:PSNL
Want to see PSNL full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.26Last Year’s EPS
-0.23Same Quarter Last Year
Strong Buy
Based on 7 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call balanced strong operational and clinical momentum (rapid test volume growth, compelling real-world and study data, growing MRD pipeline, reimbursement wins and a healthy cash balance) against material near-term financial headwinds (severe gross margin compression, higher operating expenses, widening net loss and elevated cash burn). Management frames the negative margin and revenue mix trends as intentional investments to capture MRD market share and expects margins and ASPs to improve as reimbursed volume scales, but the timing of reimbursement and conversion to higher-margin revenue remains a key risk.Company Guidance
Rapid clinical volume acceleration
Delivered >7,800 clinical tests in Q1 2026, a 26% sequential increase vs Q4 and a 258% year-over-year increase, with a 2026 annual volume target of 43,000 to 45,000 tests.
Strong clinical adoption and retention
Surpassed 1,000 ordering physicians in the quarter and reported physician retention above 98% over recent quarters, indicating deepening usage and customer stickiness.
Compelling clinical and real-world data
Key evidence highlights: NeoPrism CRC collaborators reported 100% negative predictive value for relapse in a colorectal cohort; real-world testing of 10,000 patients showed ~40% of positive detections in the ultrasensitive range (<100 ppm) across 14 cancer types; DARWIN II data showed early ctDNA clearance linked to a ~5x higher likelihood of 3-year progression-free status.
Product and roadmap progress
Launched a pilot of the real-time Variant Tracker to monitor tumor biology changes during therapy, expanding clinical utility beyond presence/absence MRD detection.
Growing MRD biopharma opportunity
Q1 biopharma MRD revenue was $3.1M with a full-year MRD revenue target of $20M–$21M; strategic revenue (clinical + biopharma MRD adoption) was $4.5M in Q1 with guidance to more than double strategic revenue to $30M–$32M for 2026.
Reimbursement progress and clinical revenue ramp
Medicare coverage wins for breast (Nov 2025) and lung (Feb 2026) surveillance are live; clinical revenue grew to $1.4M in Q1 from $0.3M in Q1 2025 (~+367%), supporting higher ASPs and future margin expansion as reimbursed volume scales.
Strong liquidity and runway
Ended Q1 with $233.2M in cash and short-term investments, no material debt, and used ~$28M of cash in Q1 (including a ~$5M one-time incentive payment), supporting planned investments to scale MRD strategy.
PSNL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
PSNL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $5.99 | $5.98 | -0.17% |
Feb 26, 2026 | $9.03 | $9.06 | +0.33% |
Nov 04, 2025 | $8.73 | $7.66 | -12.26% |
Aug 05, 2025 | $5.64 | $4.41 | -21.90% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Personalis (PSNL) report earnings?
Personalis (PSNL) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Personalis (PSNL) earnings time?
Personalis (PSNL) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is PSNL EPS forecast?
PSNL EPS forecast for the fiscal quarter 2026 (Q2) is -0.26.